| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| SVRA | SVRA | Shares | USD | XNGS |
| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| SVRA | SVRA | Shares | USD | XNGS |
Savara Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. Its lead product candidate, MOLBREEVI, is an inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). The company aims to provide improved treatment options for individuals affected by these conditions.
No recent RNS announcements for SVRA across SVRA.
No recent RNS announcements for SVRA across SVRA.